CD8A and neoplasm: On a genomic level, among the most well-studied genetic drivers of immune resistance in HCC are CTNNB1 (β-catenin) mutations, which are present in nearly 27% of HCC cases [126], which can impair DCs'recruitment and antigen presentation, resulting in diminished CD8+ T cell infiltration into the tumor parenchyma [127, 128].